Literature DB >> 9771661

Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome.

O Watanabe1, I Maruyama, K Arimura, I Kitajima, H Arimura, M Hanatani, K Matsuo, T Arisato, M Osame.   

Abstract

Crow-Fukase or POEMS syndrome of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes is a rare multisystem disorder of obscure pathogenesis that is associated with microangiopathy, neovascularization, and accelerated vasopermeability. We examined the levels of the vascular endothelial growth factor/vascular permeability factor (VEGF) in the serum and cerebrospinal fluid (CSF) from 10 patients with this syndrome. Serum VEGF levels were about 15-30 times those in control subjects or patients with Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and other neurological disorders. The CSF VEGF levels, however, were similar to those found in GBS and CIDP. Elevated VEGF levels in the serum decreased in 7 patients with Crow-Fukase syndrome after conventional therapy. The principal isoform of VEGF in Crow-Fukase syndrome was VEGF165. Elevated VEGF was independent of M-protein. Our results suggest that the overproduction of VEGF is important in the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9771661     DOI: 10.1002/(sici)1097-4598(199811)21:11<1390::aid-mus5>3.0.co;2-4

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  54 in total

Review 1.  Immunological mechanisms in paraneoplastic peripheral neuropathy.

Authors:  J C Antoine
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

2.  POEMS syndrome with severe neurological damage clinically recovered with lenalidomide.

Authors:  José F Tomás; Pilar Giraldo; Ramón Lecumberri; Sara Nistal
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  An unusual case of pulmonary hypertension in a young male.

Authors:  Carlo Rostagno; Stefania Ciolli; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

4.  Expression of vascular endothelial growth factor by plasma cells in the sclerotic bone lesion of a patient with POEMS syndrome.

Authors:  Hideto Nakajima; Shimon Ishida; Daisuke Furutama; Masakazu Sugino; Fumiharu Kimura; Taiji Yokote; Ichiro Baba; Motomu Tsuji; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2007-02-03       Impact factor: 4.849

Review 5.  Molecularly targeted therapies for dysimmune neuropathies.

Authors:  Andreas A Argyriou
Journal:  Mol Med       Date:  2009-05-05       Impact factor: 6.354

6.  Multicentric, Hyaline Vascular Variant of Castleman's Syndrome.

Authors:  V Mukta; Chandragiri Susmitha; Rakhee Kar; Debdatta Basu; A K Das
Journal:  Indian J Hematol Blood Transfus       Date:  2013-07-13       Impact factor: 0.900

7.  An unusual case of myocardial infarction.

Authors:  Sally Moore; Neil Rabin; Jamie Cavanagh; Diane Playford; Kwee Yong
Journal:  BMJ Case Rep       Date:  2010-04-05

Review 8.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

9.  Calciphylaxis as a Catastrophic Complication in a Patient with POEMS Syndrome.

Authors:  Akiyo Hineno; Tomomi Kinoshita; Michiaki Kinoshita; Fuyuko Arakura; Ko-Suke Naito; Yasuhiro Shimojima; Masayuki Matsuda; Kunihiro Yoshida; Shu-Ichi Ikeda
Journal:  Case Rep Neurol       Date:  2009-12-02

10.  Intracranial hemangiomas in a patient with POEMS syndrome.

Authors:  G D Maurer; J Schittenhelm; U Ernemann; V A J Kempf; R Ritz; M Weller; F Schmidt
Journal:  J Neurol       Date:  2009-11-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.